Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)
27.50
-0.15 (-0.54%)
Feb 4, 2026, 3:00 PM CST
SHA:603351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,305 | 1,287 | 1,152 | 1,103 | 1,032 | 729.59 |
Other Revenue | 9.94 | 9.94 | 4.21 | 8.36 | 10.24 | 6.47 |
| 1,315 | 1,297 | 1,156 | 1,111 | 1,042 | 736.06 | |
Revenue Growth (YoY) | -0.97% | 12.19% | 4.04% | 6.59% | 41.60% | -16.43% |
Cost of Revenue | 925.73 | 938.49 | 842.97 | 810.66 | 762.68 | 513.45 |
Gross Profit | 388.9 | 358.26 | 312.87 | 300.36 | 279.63 | 222.62 |
Selling, General & Admin | 122.6 | 115.84 | 121.5 | 126.32 | 107.53 | 72.8 |
Research & Development | 84.85 | 71.56 | 55.64 | 53.87 | 40.73 | 34.83 |
Other Operating Expenses | 1.92 | 1.25 | 3.23 | 7.6 | 6.77 | 5.76 |
Operating Expenses | 209.89 | 188.99 | 180.67 | 183.31 | 157.17 | 114.63 |
Operating Income | 179.01 | 169.27 | 132.2 | 117.04 | 122.46 | 107.99 |
Interest Expense | -11.65 | -13.84 | -15.25 | -12.48 | -7.04 | -5 |
Interest & Investment Income | 0.62 | 0.93 | 0.78 | 0.63 | 1.47 | 8.5 |
Currency Exchange Gain (Loss) | 1.54 | 1.54 | 0.53 | 2.48 | -0.51 | -0.92 |
Other Non Operating Income (Expenses) | -0.88 | -0.48 | -0.03 | -0.2 | -0.71 | 0.03 |
EBT Excluding Unusual Items | 168.64 | 157.42 | 118.23 | 107.47 | 115.67 | 110.59 |
Gain (Loss) on Sale of Investments | 4.24 | 12 | 1.44 | -0.11 | 1.7 | 4.24 |
Gain (Loss) on Sale of Assets | -0.15 | -0.17 | -0.18 | -0.1 | -0.18 | -0.83 |
Asset Writedown | 1.38 | - | - | - | - | - |
Other Unusual Items | 2.87 | 2.87 | 1.95 | 5.59 | 1.54 | 4.28 |
Pretax Income | 176.98 | 172.13 | 121.44 | 112.85 | 118.74 | 118.28 |
Income Tax Expense | 31.07 | 26.93 | 12.33 | 18.42 | 18.59 | 17.83 |
Earnings From Continuing Operations | 145.91 | 145.21 | 109.11 | 94.43 | 100.15 | 100.45 |
Net Income to Company | 145.91 | 145.21 | 109.11 | 94.43 | 100.15 | 100.45 |
Minority Interest in Earnings | 1.68 | 1.22 | 3.08 | 0.6 | 1.22 | - |
Net Income | 147.59 | 146.42 | 112.2 | 95.03 | 101.37 | 100.45 |
Net Income to Common | 147.59 | 146.42 | 112.2 | 95.03 | 101.37 | 100.45 |
Net Income Growth | 0.52% | 30.50% | 18.07% | -6.26% | 0.92% | -21.59% |
Shares Outstanding (Basic) | 135 | 136 | 135 | 132 | 133 | 130 |
Shares Outstanding (Diluted) | 135 | 136 | 135 | 134 | 133 | 130 |
Shares Change (YoY) | -0.43% | 0.29% | 1.00% | 0.35% | 2.25% | 1.83% |
EPS (Basic) | 1.09 | 1.08 | 0.83 | 0.72 | 0.76 | 0.77 |
EPS (Diluted) | 1.09 | 1.08 | 0.83 | 0.71 | 0.76 | 0.77 |
EPS Growth | 0.95% | 30.12% | 16.90% | -6.58% | -1.30% | -23.00% |
Free Cash Flow | 146.9 | 170.34 | 47.17 | -124.91 | -247.16 | -189.13 |
Free Cash Flow Per Share | 1.08 | 1.26 | 0.35 | -0.93 | -1.85 | -1.45 |
Dividend Per Share | 0.400 | 0.400 | 0.300 | 0.280 | 0.300 | 0.300 |
Dividend Growth | 33.33% | 33.33% | 7.14% | -6.67% | - | -6.66% |
Gross Margin | 29.58% | 27.63% | 27.07% | 27.03% | 26.83% | 30.24% |
Operating Margin | 13.62% | 13.05% | 11.44% | 10.54% | 11.75% | 14.67% |
Profit Margin | 11.23% | 11.29% | 9.71% | 8.55% | 9.73% | 13.65% |
Free Cash Flow Margin | 11.17% | 13.14% | 4.08% | -11.24% | -23.71% | -25.70% |
EBITDA | 314.85 | 276.06 | 200.26 | 180.62 | 162.12 | 142.33 |
EBITDA Margin | 23.95% | 21.29% | 17.33% | 16.26% | 15.55% | 19.34% |
D&A For EBITDA | 135.84 | 106.79 | 68.06 | 63.58 | 39.66 | 34.34 |
EBIT | 179.01 | 169.27 | 132.2 | 117.04 | 122.46 | 107.99 |
EBIT Margin | 13.62% | 13.05% | 11.44% | 10.54% | 11.75% | 14.67% |
Effective Tax Rate | 17.55% | 15.64% | 10.15% | 16.32% | 15.65% | 15.08% |
Revenue as Reported | 1,315 | 1,297 | 1,156 | 1,111 | 1,042 | 736.06 |
Advertising Expenses | - | 1.09 | 1.82 | 0.39 | 0.61 | 0.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.